Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,629 shares of the biopharmaceutical company's stock after buying an additional 955 shares during the quarter. Regeneron Pharmaceuticals accounts for about 1.5% of China Universal Asset Management Co. Ltd.'s portfolio, making the stock its 12th largest position. China Universal Asset Management Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $16,255,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $25,000. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Finally, Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. The Goldman Sachs Group reduced their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Bank of America reduced their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. Finally, Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $822.58.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $9.25 during mid-day trading on Monday, reaching $538.11. The company's stock had a trading volume of 959,668 shares, compared to its average volume of 907,598. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company's 50 day moving average is $549.38 and its two-hundred day moving average is $624.74. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The stock has a market cap of $58.09 billion, a PE ratio of 13.70, a P/E/G ratio of 2.00 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the company earned $9.55 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.